BA Oxford University 1997 BM BCh Oxford University 2000 FRCS England 2009 PhD University of Nottingham 2012
Oxford University 1994-2000
East Midlands Neurosurgery Training Programme 2004-2013 NIHR Neuro-Oncology Research Fellow 2009-2012
Clinical Associate Professor Neurosugery University of Nottingham Brain and CNS NIHR Cancer Research Lead, East Midlands
Society of British Neurological Surgeons; British Neuro-Oncology Society
Neuro-oncology including 5ALA fluorescence guided surgery, awake craniotomy, ultrasound guided surgery, low grade glioma surgery
Core member Neuro-Oncology MDT; Research Lead for Neurosurgery Dept.
I am developing an active translational and clinical research programme in Nottingham, collaborating with the Children's Brain Tumour Research Centre, extending their work to an all age programme. I am particularly interested in high grade glial tumours, with studies running looking at drug delivery to these tumours, intra-tumour heterogeneity, microRNA profiling and metabolic control within these tumours.
1. Smith SJ, Rahman CV, Clarke PA, Ritchie AA, Gould TW, Ward JH, Shakesheff KM, Grundy RG and Rahman R Surgical delivery of drug-releasing poly(lactic-co-glycolic acid) / poly(ethylene glycol) paste with in-vivo effects against glioblastoma Annals RCSEng 2. Rahman CV, Smith SJ, Morgan PS, Langmack KA, Macarthur DC, Rose FRAJ, Shakesheff KM, Grundy RG, Rahman R Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable micro-particle based matrix. PloS one. 2013;8(10):e77435. PubMed PMID: 24155955. Pubmed Central PMCID: PMC3796488. Epub 2013/10/25. eng. 3. Smith SJ, Wilson M, Ward JH, Rahman CV, Peet AC, Macarthur DC, Rose FRAJ, Grundy RG, Rahman R Recapitulation of neoplastic phenotypes and molecular signatures in 3D brain cancer aggregates with decreased sensitivity to histone deacetylase inhibition. PLOSone 2012;7(12):e52335. 4. Smith SJ*, Tilly H, Macarthur DC, Lowe J, Coyle B, Grundy RG CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathologica 2012 124(1):99-110 PMID: 22311740 IF: 9.7 5. Smith SJ, Long A, Barrow JH, Macarthur DC, Coyle B, Grundy RG Pediatric High Grade Glioma : Identification of Poly(ADP-ribose) Polymerase as a Potential Therapeutic Target Neuro-Oncology 2011 13(11):1171-77 IF: 6.1
Understanding activity pie charts
What does the Consultant activity pie chart show?
The Consultant activity pie charts represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.
Please note that for Consultants who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.
Understanding mortality funnel plot charts
What does the Consultant funnel plot chart show?
The Hospital Consultant mortality funnel plot represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.
The mortality presented here is for three years: April 2014 – March 2017. Please note that for Consultant who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.
The horizontal yellow line represents the national average mortality. The solid black lines above and below the yellow line are the control limits. The upper control limit represents the highest expected mortality rate. The Consultant's outcome is highlighted in magenta.